TABLE 2.
Characteristics of ex vivo functional CD8+ repertoire against HIV and EBV in 34 HIV-1-seropositive patients
| Patient | HLA | T-cell count (CD4/CD8)/ μl of blood | Plasma HIV RNA (copies/ml) | Positive HIV peptides
|
Positive EBV peptides
|
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Frequency (no. of peptides recognized by patient/total no. tested) | No. of IFN-γ SFC/ 106 PBMC
|
Frequency (no. of peptides recognized by patient/total no. tested) | No. of IFN-γ SFC/ 106 PBMC
|
||||||||
| Totala | Meanb | Range | Total | Mean | Range | ||||||
| Z134 | A24/31, B35/40 | 27/825 | 316,000 | 5/11 | 2,020 | 404 | 100–905 | 1/2 | 80 | ||
| Z136 | A1/30, B8/13 | 30/355 | 2,503,000 | 4/12 | 3,015 | 753 | 60–2,370 | 0/2 | 0 | ||
| Z130 | A1/32, B8/27 | 67/1085 | 575,000 | 7/17 | 2,736 | 390 | 90–1,172 | 0/1 | 0 | ||
| Z001 | A2/24, B35/44 | 117/911 | NDc | 6/19 | 5,019 | 836 | 100–1,610 | 2/4 | 590 | 295 | 140–450 |
| C03M | A2/68, B15/35 | 157/1837 | 72,000 | 1/8 | 50 | 0/1 | 0 | ||||
| Z132 | A3/25, B18/61 | 163/1092 | 316,000 | 3/7 | 478 | 159 | 81–263 | ND | ND | ||
| C02M | A2/−, B44/51 | 190/857 | 36,000 | 1/10 | 230 | 1/3 | 80 | ||||
| P08 | A2/28, B35/53 | 201/821 | 15,800 | 2/11 | 3,416 | 1,708 | 416–3,000 | 2/2 | 196 | 98 | 53–143 |
| Z006 | A2/24, B7/37 | 220/1180 | ND | 3/11 | 4,551 | 1,517 | 186–3,163 | 1/2 | 132 | ||
| C017M | A3/30, B44/65 | 227/653 | 1,100 | 3/12 | 3,735 | 1,245 | 214–3,000 | 0/3 | 0 | ||
| P38 | A2/3, B7/55 | 249/1247 | ND | 8/20 | 6,407 | 800 | 25–2,610 | 2/2 | 242 | 121 | 38–204 |
| Z044 | A2/25, B18/44 | 291/834 | 0 | 5/16 | 9,071 | 1,814 | 368–6,700 | 1/3 | 58 | ||
| Z020 | A2/24, B18/44 | 293/1174 | ND | 5/15 | 2,793 | 558 | 28–1,716 | 1/3 | 64 | ||
| P04 | A1/2, B8/44 | 303/1272 | 440,000 | 3/15 | 726 | 242 | 80–410 | 1/1 | 27 | ||
| C014M | A3/31, B38/51 | 308/831 | 190 | 4/9 | 695 | 173 | 59–467 | ND | ND | ||
| Z129 | A2/11, B51/62 | 323/985 | 19,500 | 7/16 | 7,520 | 1,074 | 70–3,000 | 2/2 | 1,055 | 527 | 88–967 |
| Z131 | A3/31, B14/60 | 328/567 | 329,000 | 2/9 | 536 | 268 | 115–421 | ND | ND | ||
| P36 | A2/9, B12/12 | 329/988 | 76,000 | 4/13 | 4,401 | 1,100 | 441–1,516 | 0/3 | 0 | ||
| Z077 | A2/2, B7/50 | 334/1161 | 250,000 | 5/10 | 6,663 | 1,332 | 168–3,542 | 2/3 | 311 | 155 | 148–163 |
| Z118 | A24/−, B7/42 | 346/612 | 11,000 | 6/8 | 4,803 | 800 | 17–1,744 | 2/3 | 155 | 77 | 26–129 |
| C022M | A3/32, B7/62 | 476/537 | 27,000 | 6/14 | 841 | 140 | 6–449 | 2/2 | 180 | 90 | 18–162 |
| Z067 | A1/2, B7/8 | 490/5000 | ND | 8/18 | 16,413 | 2,051 | 120–7,260 | 0/3 | 0 | ||
| Z112 | A2/−, B7/61 | 513/ND | ND | 6/12 | 1,825 | 304 | 25–870 | 2/3 | 130 | 65 | 50–80 |
| Z050 | A1/3, B8/35 | 545/545 | 29,763 | 8/19 | 5,495 | 686 | 10–3,090 | 1/2 | 555 | ||
| Z028 | A11/23, B7/49 | 598/988 | 25,000 | 7/9 | 2,286 | 326 | 19–863 | 3/3 | 862 | 287 | 137–432 |
| P09 | A2/24, B12/17 | 600/844 | 112,000 | 4/14 | 1,542 | 385 | 25–1,100 | 1/3 | 331 | ||
| Z108 | A2/31, B44/44 | 666/1214 | 69,000 | 4/17 | 8,047 | 2,011 | 242–6,455 | 2/3 | 1,856 | 928 | 195–1661 |
| Z042 | A1/32, B7/8 | 709/2747 | 31,000 | 6/17 | 4,602 | 767 | 32–1,448 | 3/3 | 560 | 186 | 27–460 |
| P51 | A31/32, B8/27 | 787/1952 | 122,000 | 9/17 | 4,581 | 509 | 60–1,177 | 1/1 | 651 | ||
| Z100 | A2/32, B40/44 | 858/1201 | ND | 4/13 | 605 | 151 | 55–280 | 1/3 | 140 | ||
| Z038 | A3/11, B35/44 | 945/936 | 0 | 13/16 | 12,933 | 994 | 51–4,879 | 1/3 | 1,344 | ||
| Z059 | A11/30, B44/55 | 952/1224 | 0 | 6/13 | 1,391 | 231 | 32–755 | 2/4 | 165 | 82 | 15–150 |
| P01 | A1/9, B8/15 | ND/ND | ND | 5/11 | 4,796 | 1,128 | 149–2,223 | 1/1 | 898 | ||
| Z039 | A2/3, B27/38 | ND/ND | ND | 5/13 | 4,634 | 926 | 300–1,824 | ND | ND | ||
a
Sum of the numbers of SFC per 106 PBMC for all viral peptides recognized.
b
Total intensity divided by number of peptides recognized.
c
ND, not done.